Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 9/20 | 0.59 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CCR1 | P32246 | 1/20 | 0.31 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
| ▸ | CCR8 | P51685 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6627221 | 0.83 | — | — | |
| SCHEMBL20860587 | 0.81 | GRM4 (0.61) | GRM4HDAC6KDM4EALDH1A1HPGD | |
| SCHEMBL17053108 | 0.77 | GRM4 (0.57) | GRM4HDAC6KDM4EALDH1A1RAB9A | |
| SCHEMBL25170582 | 0.77 | GRM4 (0.57) | GRM4HDAC6KDM4EALDH1A1RAB9A | |
| SCHEMBL30404869 | 0.77 | GRM4 (0.57) | GRM4HDAC6KDM4EALDH1A1RAB9A | |
| SCHEMBL22917316 | 0.76 | GRM4 (0.56) | GRM4HDAC6KDM4EALDH1A1HPGD | |
| SCHEMBL31029406 | 0.76 | GRM4 (0.56) | GRM4HDAC6KDM4EALDH1A1HPGD | |
| SCHEMBL20069379 | 0.76 | GRM4 (0.51) | GRM4HDAC6KDM4ENPC1RAB9A | |
| SCHEMBL25403351 | 0.76 | — | — | |
| SCHEMBL33532921 | 0.75 | GRM4 (0.54) | GRM4HDAC6KDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | claimed |
| US-20050192339-A1 | Compounds | BIOVITRUM AB (SE) | 2005-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192339-A1 | Compounds | MCHR1, HCRTR1, NPY1R | GRM4 776/4885HDAC6 1335/4885KDM4E 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.